Clinical Trials Logo

Myocardial Ischemia clinical trials

View clinical trials related to Myocardial Ischemia.

Filter by:

NCT ID: NCT04224714 Active, not recruiting - Myocardial Ischemia Clinical Trials

Clinical Study on the Correlation Between IMR(Index of Microcirculation Resistance) and FFR(Fractional Flow Reserve)

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

To study the effect of myocardial microcirculation disturbance on coronary flow reserve fraction, compare the evaluation value of IMR, FFR and QCA on myocardial ischemia, and discuss the correlation among them.

NCT ID: NCT04175626 Active, not recruiting - Clinical trials for Coronary Artery Disease

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

BIOFLOW-VII
Start date: January 24, 2020
Phase:
Study type: Observational

The objective of this post-approval study is to confirm that the clinical performance of the Orsiro stent in a real-world setting is similar to the clinical performance observed for Orsiro in the BIOFLOW-V Investigational Device Exemption pivotal trial, as a condition of the US Food and Drug Administration (FDA) approval (P170030).

NCT ID: NCT04172870 Active, not recruiting - Clinical trials for Coronary Artery Disease

Evaluation of Inflammatory Markers and Periodontal Viruses on Periodontitis Patients With CAD

Start date: November 15, 2018
Phase:
Study type: Observational

To assess and compare the demographic variables, periodontal parameters, cardiac parameters and the expression of periodontal viruses (CMV, HSV and EBV) and inflammatory biomarkers(PTX-3, TLR-2 & TLR-4) in periodontally healthy and generalized periodontitis patients with and without coronary artery disease(CAD).

NCT ID: NCT04148833 Active, not recruiting - Clinical trials for Coronary Artery Disease

Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles

PAC-MAN
Start date: June 23, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators propose a prospective, randomized, double-blind, placebo-controlled study. The purpose of the study is to evaluate the safety and efficacy of an anti-proliferative agent paclitaxel in a cholesterol-rich non-protein nanoparticle (Paclitaxel -LDE) in patients with stable coronary disease. Patients with multi-vessels stable coronary disease will be randomized to receive Paclitaxel-LDE IV or placebo-LDE IV each 21 days for 6 weeks. The primary and main secondary endpoints will be analyzed by coronary and aortic CTA, that will be performed 1-4 weeks after randomization and at 3-8 weeks after the last treatment cycle. Patients will undergo clinical and laboratory safety evaluations before each treatment cycle and 3-8 weeks after the last cycle. An algorithm for drug suspension based on clinical and laboratory finding will be followed.

NCT ID: NCT04098042 Active, not recruiting - Clinical trials for Coronary Artery Disease

MAGnesIum Alloy Scaffold for Coronary Artery Disease (MAGIC)

MAGIC
Start date: July 30, 2016
Phase:
Study type: Observational

The retrospective study will investigate the clinical performance and long-term safety of scaffold implantation in a real world setting including high volume PCI centers in Italy

NCT ID: NCT04009421 Active, not recruiting - Clinical trials for Coronary Artery Disease

Coronary Artery Plaque Burden in Stable Angina and Non-obstructive Coronary Artery Disease

Start date: February 15, 2018
Phase:
Study type: Observational [Patient Registry]

Non-obstructive coronary artery disease (CAD), particularly common in women, has been associated with impaired quality of life and risk of recurrent hospitalizations. Several studies have also demonstrated increased risk of incident acute coronary events and mortality. The main objective of the project is to assess the association between coronary artery plaque features by coronary CT angiography and long term prognosis in a large unselected population undergoing CT coronary angiography due to stable angina and suspected myocardial ischemia from the Norwegian Registry for Invasive Cardiology (NORIC) diagnosed with non-obstructive CAD by coronary CT angiography.

NCT ID: NCT03978130 Active, not recruiting - Clinical trials for Ischemic Heart Disease

Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease

RESILIENT
Start date: January 9, 2020
Phase: N/A
Study type: Interventional

RESILIENT is a phase II, multi-center, prospective, pragmatic randomized clinical trial with blinded assessment of the primary endpoint. This study aims to evaluate whether mHealth-CR improves functional capacity in older adults (age ≥65) with IHD compared with standard traditional cardiac rehabilitation care. A total of 400 eligible patients will be randomized in 3:1 manner to mHealth-CR versus usual care for assessment of primary endpoint. Enrollment will occur over approximately 42 months with an expected minimum of 3 months follow-up per participant.

NCT ID: NCT03939468 Active, not recruiting - Clinical trials for Coronary Artery Disease

Drug-Coated Balloon in Combination With New Generation Drug-Eluting Stent for de Novo Diffuse Disease Treatment

HYPER
Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

A Pilot Observational Study to evaluate safety and efficacy of the hybrid approach DES/DCB in treating de-novo diffuse lesions

NCT ID: NCT03928119 Active, not recruiting - Clinical trials for Acute Myocardial Infarction

reGional Network for Acute Myocardial Infarction

GAMI
Start date: August 1, 2015
Phase: N/A
Study type: Interventional

Incidence of ST-segment Elevation Myocardial Infarction (STEMI) is rising and the existing emergency medical aid system for STEMI was not enough for timely perfusion treatment. No existing research with high-quality data focuses on the characteristic of STEMI incidence and regional network construction. Aiming of Guangdong GAMI(reGional network for Acute Myocardial Infarction) project is to establish effective collaborative regional network system for STEMI patients treatment.

NCT ID: NCT03907891 Active, not recruiting - Covid19 Clinical Trials

Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations

Heart Up!
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

After a 30-year decline, heart disease is projected to increase up to 18% by 2030. Participation rates in cardiac rehabilitation remain extremely low and hopeless individuals are less likely to participate. This innovative study has the potential to advance science, improve patient care, and improve patient outcomes by demonstrating the effectiveness of the Heart Up! program to increase physical activity and reduce hopelessness in patients with heart disease. Hopelessness is associated with a 3.4 times increased risk of mortality or nonfatal myocardial infarction in patients with ischemic heart disease (IHD), independent of depression. Hopelessness has been identified in 27-52% of patients with IHD and can persist for up to 12 months after hospital discharge. Hopelessness, a negative outlook and sense of helplessness toward the future, can be a temporary response to an event (state) or a habitual outlook (trait). Hopelessness is associated with decreased physical functioning and lower physical activity (PA) levels in individuals with IHD. While research has investigated strategies to increase PA among IHD patients in general, the study team is the only group to design an intervention to promote PA specifically in hopeless IHD patients. The purpose of this randomized controlled trial is to establish the effectiveness of our 6-week mHealth intervention (Heart Up!) to promote increased PA in hopeless patients with IHD. A total of 225 hopeless IHD patients will be enrolled from a large community teaching hospital in the Midwest. Patients will be randomized (75 per group) to one of three groups: 1) motivational social support (MSS) from a nurse, 2) MSS from a nurse with additional significant other support (SOS), or 3) attention control (AC). It is hypothesized that 1) The MSS with SOS group will have the greatest increase in average minutes of moderate to vigorous PA per day at 8 and 24 weeks as compared to the MSS only or AC groups; 2) Greater increase in minutes of moderate to vigorous PA per day will be associated with decreased state hopelessness levels from baseline to weeks 8 and 24; and 3) Increased social support and increased motivation will mediate the effects of Heart Up! on a greater increase in moderate to vigorous PA at 8 and 24 weeks. The findings from this study could transform care for IHD patients who are hopeless by promoting self-management of important PA goals that can contribute to better health outcomes.